Series A · Biotech · Vienna, Austria · Founded 2021 · 11–50 employees
Vienna-based biotech invIOs is a clinical-stage company developing next-generation cancer immunotherapies for difficult-to-treat indications such as glioblastoma, melanoma, and lung cancer. The company utilizes its proprietary EPiC platform to rapidly process and modify patient immune cells in outpatient settings, bypassing the immunosuppressive environments of tumors. In October 2024, invIOs secured an 8.2 million EUR Series A funding round to advance its clinical pipeline through 2025. The company's clinical development is supported by public grants from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (aws), validating its novel approaches in cell therapy.
No open roles listed right now.